The results from this study indicate that CSP exhibits healing effects in an NAFLD model and that the network pharmacology approach to screening NR targets and determining the corresponding CSP components is a practical strategy for explaining the mechanism by which CSP ameliorates NAFLD. This evidence concerns the gene DNAJC5 and metabolic dysfunction-associated steatotic liver disease.